BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:24 PM
 | 
Jan 17, 2018
 |  BC Extra  |  Clinical News

Exact Sciences falls on CellMax cancer diagnostic data

Exact Sciences Corp. (NASDAQ:EXAS) was off $5.27 (10%) to $47.68 on Wednesday after CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. The data were released in an abstract ahead of this week's American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

CellMax markets...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >